Crinetics (NASDAQ: CRNX) COO-level executive Jeff Knight to resign by April 10, 2026

Rhea-AI Filing Summary

Crinetics Pharmaceuticals announced that Jeff Knight has decided to resign as Chief Development and Operating Officer, effective on or about April 10, 2026. The company states that he is leaving to pursue another opportunity and that his resignation is not due to any disagreement over operations, policies, or practices.

Crinetics plans to reassign all of Mr. Knight’s managerial responsibilities and direct reports to other members of its executive leadership team, signaling a redistribution of his duties rather than the creation of a new replacement role at this time.

Insights

Biopharma corporate governance analyst

Senior operating executive departs; duties redistributed internally.

The departure of the Chief Development and Operating Officer at Crinetics Pharmaceuticals is notable because it affects leadership over development and operations. The company clarifies he is leaving to pursue another opportunity and explicitly notes no disagreements over corporate matters.

All of his responsibilities will shift to other executive leaders, indicating an internal reallocation rather than an immediate external hire. The long-term impact will depend on how smoothly this transition proceeds and whether future disclosures outline any organizational or strategic changes following his exit effective on or about April 10, 2026.

0001658247false00016582472026-03-232026-03-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________________________________________________

FORM 8-K

_________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 17, 2026

_________________________________________________________

Crinetics Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

_________________________________________________________

Delaware			001-38583			26-3744114
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
6055 Lusk Boulevard
San Diego, California						92121
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 450-6464

(Former Name or Former Address, if Changed Since Last Report)

_________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

CRNX

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 17, 2026, Jeff Knight notified Crinetics Pharmaceuticals, Inc. (the “Company”) of his decision to resign as Chief Development and Operating Officer of the Company, effective on or about April 10, 2026. Mr. Knight resigned to pursue another opportunity, and his resignation is not related to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. All of Mr. Knight’s managerial responsibilities and direct reports will be reassigned to other members of the executive leadership team.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

									Crinetics Pharmaceuticals, Inc.
Date:			March 23, 2026			By:			/s/ R. Scott Struthers, Ph.D.
									R. Scott Struthers, Ph.D. President and Chief Executive Officer (Principal Executive Officer)

FAQ

Why did Jeff Knight resign from Crinetics Pharmaceuticals (CRNX)?

Jeff Knight resigned as Chief Development and Operating Officer to pursue another opportunity. The company states his resignation is not related to any disagreement regarding operations, policies, or practices, suggesting a voluntary career move rather than a dispute-driven departure.

When will Jeff Knight’s resignation from Crinetics Pharmaceuticals (CRNX) become effective?

Jeff Knight’s resignation as Chief Development and Operating Officer is effective on or about April 10, 2026. Until then, he remains in his role while the company prepares to reassign his responsibilities to other members of its executive leadership team.

Did Jeff Knight have any disagreements with Crinetics Pharmaceuticals (CRNX) before resigning?

Crinetics Pharmaceuticals states that Jeff Knight’s resignation is not related to any disagreement with the company. This includes no disputes regarding operations, policies, or practices, indicating the departure is not tied to reported internal conflict or governance issues.

How will Crinetics Pharmaceuticals (CRNX) handle Jeff Knight’s responsibilities after his resignation?

Crinetics plans to reassign all of Jeff Knight’s managerial responsibilities and direct reports to other executive leadership team members. This approach redistributes his development and operating duties internally rather than immediately appointing a direct successor or creating a new standalone role.

What executive role did Jeff Knight hold at Crinetics Pharmaceuticals (CRNX)?

Jeff Knight served as Chief Development and Operating Officer at Crinetics Pharmaceuticals. This combined role covered leadership over drug development and operational functions, which the company now intends to redistribute among other executives following his effective resignation date in April 2026.

Does the resignation announcement for CRNX mention any changes to company strategy?

The announcement focuses on Jeff Knight’s resignation and the reassignment of his responsibilities. It does not outline specific strategic changes, instead emphasizing that duties will move to other executive leaders and that the departure is not due to disagreements over company operations or policies.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB